6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis

ACS Medicinal Chemistry Letters

Volumn 8, Issue 10, 2017, Pages 1019-1024

  Tong, Amy S T ^a   Choi, Peter J ^a   Blaser, Adrian ^a   Sutherland, Hamish S ^a   Tsang, Sophia K Y ^a   Guillemont, Jerome ^b   Motte, Magali ^b   Cooper, Christopher B ^c   Andries, Koen ^d   Van Den Broeck, Walter ^d   Franzblau, Scott G ^e   Upton, Anna M ^c   Denny, William A ^a   Palmer, Brian D ^a   Conole, Daniel ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Janssen Laboratories   (France)

^c GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ATP synthase; Bedaquiline; diarylquinoline; hERG; lipophilicity; tuberculosis

Indexed keywords

6 CYANO ANALOGUE; BEDAQUILINE; POTASSIUM CHANNEL HERG; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CHEMICAL REACTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REDUCTION (CHEMISTRY); TUBERCULOSIS;

EID: 85031292526     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.7b00196     Document Type: Article

References (21)

1. Laurenzi, M.; Ginsberg, A.; Spigelman, M. Challenges associated with current and future TB treatment Infect. Disord.: Drug Targets 2007, 7, 105-119 10.2174/187152607781001817
2. Koul, A. N.; Dendouga, K.; Vergauwen, B.; Molenberghs, B.; Vranckx, L.; Willebrords, R.; Ristic, Z.; Lill, H.; Dorange, I.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines target subunit c of mycobacterial ATP synthase Nat. Chem. Biol. 2007, 3, 323-324 10.1038/nchembio884
3. Diacon, A. H.; Donald, P. R.; Pym, A.; Grobusch, M.; Patientia, R. F.; Mahanyele, R.; Bantubani, N.; Narasimooloo, T.; De Marez, R. T.; van Heeswijk, R.; Lounis, N.; Meyvisch, K.; Andries, K.; McNeeley, D. F. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance Antimicrob. Agents Chemother. 2012, 56, 3271-3276 10.1128/AAC.06126-11
4. Global Alliance for TB. Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824). http://www.tballiance.org/newscenter/view-brief.php?id=1114 (published 29 January 2015).
5. Diacon, A. H.; Dawson, R.; von Groote-Bidlingmaier, F.; Symons, G.; Venter, A.; Donald, P. R.; van Niekerk, C.; Everitt, D.; Hutchings, J.; Burger, D. A.; Schall, R.; Mendel, C. M. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline Am. J. Respir. Crit. Care Med. 2015, 191, 943-953 10.1164/rccm.201410-1801OC
6. Treatment of patients with MDR-TB. Briefing document, TMC 207 (bedaquiline). Anti-infective Drugs Advisory Committee, NDA 204-384 (28 November 2014).
7. Kakkar, A. K.; Dahiya, N. Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls Tuberculosis 2014, 94 (4) 357-362 10.1016/j.tube.2014.04.001
8. Mesens, N.; Verbeeck, J.; Rouan, M.; Vanparys, P. Elucidating the role of M2 in the preclinical safety profile of TMC207. In Abstract on the 38th Union World Conference on Lung Health, Cape Town, South Africa, 2007.
9. Svensson, E. M.; Murray, S.; Karlsson, M. O.; Dooley, K. E. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug J. Antimicrob. Chemother. 2015, 70, 1106-1114 10.1093/jac/dku504
10. Prescribing Information for Bedaquiline (PDF). http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/204384s000lbl.pdf (retrieved 20 July 2015).
11. Guillemont, J.; Meyer, C.; Poncelet, A.; Bourdrez, X.; Andries, K. Diarylquinolines, synthesis pathways and quantitative structure-activity relationship studies leading to the discovery of TMC207 Future Med. Chem. 2011, 3, 1345-1360 10.4155/fmc.11.79
12. Preiss, L.; Langer, J. D.; Yildiz, O.; Eckhardt-Strelau, L.; Guillemont, J.; Koul, A.; Meier, T. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline Sci. Adv. 2015, 1, e1500106 10.1126/sciadv.1500106
13. Saga, Y.; Motoki, R.; Makino, S.; Shimizu, Y.; Kanai, M.; Shibasaki, M. Catalytic asymmetric synthesis of R207910 J. Am. Chem. Soc. 2010, 132, 7905-07 10.1021/ja103183r
14. Chandrasekhar, S.; Kiran Babu, G. S.; Mohapatra, D. K. Practical syntheses of (2S)-R207910 and (2R)-R207910 Eur. J. Org. Chem. 2011, 2011, 2057-61 10.1002/ejoc.201001720
15. Ryber, P. Development of a mild and robust method for large-scale palladium-catalysed cyanation of aryl bromides: importance of the order of addition Org. Process Res. Dev. 2008, 12, 540-543 10.1021/op800020r
16. 3 as a precursor of soluble metal complexes and nanoparticles: determination of palladium active species for catalysis and synthesis Organometallics 2012, 31, 2302-2309 10.1021/om201217r
17. Andries, K. J. L. M.; Van Gestel, J. F. E. Preparation of aminohydroxyaralkylquinolines for the treatment of drug resistant mycobacterial diseases. WO 2005/117875.
18. Guillemont, J. E. G.; Lancois, D. F. A.; Dorange, I.; Andries, K. J. L. M.; Koul, A. Antibacterial quinoline derivatives and their preparation, and use in the treatment of bacterial infection. WO 2008/068267 A1.
19. Andries, K. J. L. M.; Koul, A.; Guillemont, J. E. G.; Pasquier, E. T. J.; Lancois, D. F. A. Preparation of aminohydroxyphenylbutylquinolines as antibacterials. WO 2006/131519 A1.
20. Collins, L. A.; Franzblau, S. G. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother. 1997, 41, 1004-1009
21. +) channel blockade: current knowledge and strategies for the early prediction during drug development Med. Res. Rev. 2005, 25, 133-166 10.1002/med.20019